{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:10:16Z","timestamp":1768547416126,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"am","delay-in-days":451,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jacl.2024.07.002","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T21:15:56Z","timestamp":1721250956000},"page":"e844-e854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum mature and furin-cleaved proprotein convertase subtilisin\/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1543-1183","authenticated-orcid":false,"given":"Kiyoshi","family":"Hibi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Gohbara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4810-3570","authenticated-orcid":false,"given":"Noriaki","family":"Iwahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kozo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-109X","authenticated-orcid":false,"given":"Yoshihiro","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Hiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Iimuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3863-0492","authenticated-orcid":false,"given":"Ichiro","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Hokimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7534-4826","authenticated-orcid":false,"given":"Hiroaki","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masunori","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryozo","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2024.07.002_bib0001","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jacasi.2021.10.003","article-title":"The PCSK9 problem: is it predictive, punitive, or puzzling?","volume":"1","author":"Pamir","year":"2021","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacl.2024.07.002_bib0002","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2024.07.002_bib0003","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2024.07.002_bib0004","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","article-title":"Circulating proprotein convertase subtilisin\/kexin Type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors","volume":"133","author":"Leander","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2024.07.002_bib0005","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacbts.2016.06.007","article-title":"Circulating PCSK9 and risk of myocardial infarction: the HUNT Study in Norway","volume":"1","author":"Laugsand","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacl.2024.07.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106294","article-title":"Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies","volume":"9","author":"Almontashiri","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jacl.2024.07.002_bib0007","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/07853890.2015.1042908","article-title":"Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease","volume":"47","author":"Li","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.jacl.2024.07.002_bib0008","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.diabet.2017.07.009","article-title":"Circulating PCSK9 levels in acute coronary syndrome: results from the PC-SCA-9 prospective study","volume":"43","author":"Cariou","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jacl.2024.07.002_bib0009","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4093\/dmj.2017.0081","article-title":"Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome","volume":"42","author":"Bae","year":"2018","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jacl.2024.07.002_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005764","article-title":"Circulating levels of proprotein convertase subtilisin\/kexin Type 9 and arterial stiffness in a large population sample: data from the brisighella heart study","volume":"6","author":"Ruscica","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2024.07.002_bib0011","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.metabol.2013.01.005","article-title":"Association of serum proprotein convertase subtilisin\/kexin type 9 with carotid intima media thickness in hypertensive subjects","volume":"62","author":"Lee","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2024.07.002_bib0012","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijcard.2016.04.103","article-title":"Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study","volume":"215","author":"Xie","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2024.07.002_bib0013","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/2047487317693938","article-title":"Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: the Ludwigshafen risk and cardiovascular health study","volume":"24","author":"Silbernagel","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2024.07.002_bib0014","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","article-title":"Prognostic value of PCSK9 levels in patients with acute coronary syndromes","volume":"37","author":"Gencer","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2024.07.002_bib0015","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/eurheartj\/ehv568","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9 levels and the risk of first cardiovascular events","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2024.07.002_bib0016","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/ATVBAHA.115.306172","article-title":"Association of proprotein convertase subtilisin\/Kexin Type 9 (PCSK9) with cardiovascular risk in primary prevention","volume":"35","author":"Zhu","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2024.07.002_bib0017","doi-asserted-by":"crossref","first-page":"43482","DOI":"10.1074\/jbc.M112.380618","article-title":"Furin-cleaved proprotein convertase subtilisin\/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels","volume":"287","author":"Lipari","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2024.07.002_bib0018","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1074\/jbc.M110.192104","article-title":"In vivo evidence that furin from hepatocytes inactivates PCSK9","volume":"286","author":"Essalmani","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2024.07.002_bib0019","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1210\/jc.2014-3066","article-title":"Removal of plasma mature and furin-cleaved proprotein convertase subtilisin\/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9","volume":"100","author":"Hori","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2024.07.002_bib0020","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.117.032615","article-title":"High-dose versus low-dose pitavastatin in japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial","volume":"137","author":"Taguchi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2024.07.002_bib0021","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.0006-341X.2004.00257.x","article-title":"Sample size\/power calculation for case-cohort studies","volume":"60","author":"Cai","year":"2004","journal-title":"Biometrics"},{"key":"10.1016\/j.jacl.2024.07.002_bib0022","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2024.07.002_bib0023","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2024.07.002_bib0024","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2024.07.002_bib0025","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2024.07.002_bib0026","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjcvp\/pvaa077","article-title":"2019 ESC\/EAS Guidelines for management of dyslipidaemia: strengths and limitations","volume":"7","author":"Zeitouni","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacl.2024.07.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.002043","article-title":"Characterization of statin low-density lipoprotein cholesterol dose-response using electronic health records in a large population-based cohort","volume":"11","author":"Oni-Orisan","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacl.2024.07.002_bib0028","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/ije\/dyad011","article-title":"Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345 000 men and women aged 20-79 years","volume":"52","author":"M\u00f8rland","year":"2023","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jacl.2024.07.002_bib0029","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.vph.2014.03.004","article-title":"Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment","volume":"62","author":"Werner","year":"2014","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jacl.2024.07.002_bib0030","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.athplu.2022.09.002","article-title":"The circulating furin-cleaved\/mature PCSK9 ratio has a potential prognostic significance in statin-na\u00efve patients with acute ST elevation myocardial infarction","volume":"50","author":"Sawaguchi","year":"2022","journal-title":"Atheroscler Plus"},{"key":"10.1016\/j.jacl.2024.07.002_bib0031","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jjcc.2020.04.006","article-title":"Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction","volume":"76","author":"Nakamura","year":"2020","journal-title":"J Cardiol"},{"key":"10.1016\/j.jacl.2024.07.002_bib0032","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1373\/clinchem.2011.172932","article-title":"Proprotein convertase subtilisin\/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial","volume":"58","author":"Awan","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2024.07.002_bib0033","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1194\/jlr.M049346","article-title":"Isolation and characterization of the circulating truncated form of PCSK9","volume":"55","author":"Han","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2024.07.002_bib0034","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase (PC) PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and post-translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2024.07.002_bib0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jacasi.2021.09.003","article-title":"Circulating furin-cleaved proprotein convertase subtilisin\/kexin type 9 concentration predicts future coronary events in Japanese subjects","volume":"1","author":"Kataoka","year":"2021","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacl.2024.07.002_bib0036","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/dom.12536","article-title":"Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials","volume":"17","author":"Sahebkar","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacl.2024.07.002_bib0037","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019525","article-title":"Circulating mature PCSK9 level predicts diminished response to statin therapy","volume":"10","author":"Kuyama","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287424002125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287424002125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:32:01Z","timestamp":1739345521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287424002125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1933287424002125"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2024.07.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum mature and furin-cleaved proprotein convertase subtilisin\/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2024.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}